Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yanping Kong maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This single action is assigned to 1 distinct examiner, which represents the current point of interaction with the USPTO.
The work is conducted within 1 distinct art unit, aligning with the requirements of the Biotechnology & Pharmaceuticals field. Paul Randall Gauger is the busiest examiner for this portfolio and is currently responsible for the 1 pending office action. As there is 1 pending action, this examiner handles the current active correspondence for the company.
Practitioners should note that the outcome of this 1 pending office action is the current focus for the development of the portfolio. The involvement of 1 distinct examiner and 1 distinct art unit means that the prosecution strategy is directed toward a single individual and unit. Success in this 1 pending office action will depend on addressing the specific concerns of Paul Randall Gauger within the context of the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GAUGER, PAUL RANDALL | 1 | 59.3% | +8.3% |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18272939 | COMPOSITIONS AND METHODS FOR TREATING CANCER | GAUGER, PAUL RANDALL | 1629 | §112 | Final Rejection | — | Pending | Jul 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYanping Kong has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Randall Gauger has the most, with 1 of Yanping Kong's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
